Shara Regina-Silva1, Ana Maria Leonardi Tibúrcio Feres2, João Carlos França-Silva3, Edelberto Santos Dias1, Érika Monteiro Michalsky1, Hélida Monteiro de Andrade3, Eduardo Antonio Ferraz Coelho4, Gustavo Meirelles Ribeiro5, Ana Paula Fernandes6, George Luiz Lins Machado-Coelho7. 1. Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil. 2. Inova Biotecnologia Saúde Animal Ltda, Juatuba, Minas Gerais, Brazil. 3. Departamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. 4. Setor de Patologia Clínica, Colégio Técnico, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. 5. Escola de Medicina, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil. 6. Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. 7. Escola de Medicina, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil. Electronic address: gmcoelho@medicina.ufop.br.
Abstract
BACKGROUND: A canine vaccine remains a promising approach for effective control of visceral leishmaniasis (VL), given its complex epidemiology in areas where zoonotic VL is prevalent. Leish-Tec(®) is a recombinant vaccine, based on the Leishmania A2 antigen, against canine VL (CVL). It is, since 2014, the single commercial vaccine licensed in Brazil. Here, Leish-Tec(®) efficacy was estimated through a randomized field trial (RFT), in a highly VL endemic area. METHODS: The RFT was conducted from 2008 to 2010 in an endemic area of southeastern Brazil, presenting a CVL seroprevalence of 41.9%. Eight hundred forty-seven seronegative dogs were randomly selected to receive Leish-Tec(®) (n=429) or placebo (n=418). Animals were followed up by clinical, serological, and parasitological exams for 18 months. The CVL incidence in both groups was compared through proportion analysis. RESULTS: A significant reduction in the number of cases of CVL was observed in the vaccine group, as compared with the placebo group, whether efficacy was estimated according to parasitological results (71.4%; 95% CI: 34.9-87.3%; p=0.001; risk ratio=0.287), by adding results of xenodiagnosis and parasitological exams (58.1%; 95% CI: 26.0-76.3%; p=0.002; risk ratio=0.419). Among the animals that converted to a positive anti-A2 serology, efficacy reached 80.8% (95% CI: 37.6-94.1%, p=0.001; risk ratio=0.192). Xenodiagnosis has detected a reduction of 46.6% (p=0.05) in transmission to sand flies from vaccinated animals presenting anti-A2 positive serology. CONCLUSION: The Leish-Tec(®) vaccine proved significantly effective for prophylaxis of CVL, after natural challenge assured by transmission of Leishmania parasites, in a highly endemic area. Noteworthy, this report has unveiled the complexity of performing a RFT for anti-CVL vaccines in Brazil, which may be helpful for designing of future studies.
BACKGROUND: A canine vaccine remains a promising approach for effective control of visceral leishmaniasis (VL), given its complex epidemiology in areas where zoonotic VL is prevalent. Leish-Tec(®) is a recombinant vaccine, based on the Leishmania A2 antigen, against canine VL (CVL). It is, since 2014, the single commercial vaccine licensed in Brazil. Here, Leish-Tec(®) efficacy was estimated through a randomized field trial (RFT), in a highly VL endemic area. METHODS: The RFT was conducted from 2008 to 2010 in an endemic area of southeastern Brazil, presenting a CVL seroprevalence of 41.9%. Eight hundred forty-seven seronegative dogs were randomly selected to receive Leish-Tec(®) (n=429) or placebo (n=418). Animals were followed up by clinical, serological, and parasitological exams for 18 months. The CVL incidence in both groups was compared through proportion analysis. RESULTS: A significant reduction in the number of cases of CVL was observed in the vaccine group, as compared with the placebo group, whether efficacy was estimated according to parasitological results (71.4%; 95% CI: 34.9-87.3%; p=0.001; risk ratio=0.287), by adding results of xenodiagnosis and parasitological exams (58.1%; 95% CI: 26.0-76.3%; p=0.002; risk ratio=0.419). Among the animals that converted to a positive anti-A2 serology, efficacy reached 80.8% (95% CI: 37.6-94.1%, p=0.001; risk ratio=0.192). Xenodiagnosis has detected a reduction of 46.6% (p=0.05) in transmission to sand flies from vaccinated animals presenting anti-A2 positive serology. CONCLUSION: The Leish-Tec(®) vaccine proved significantly effective for prophylaxis of CVL, after natural challenge assured by transmission of Leishmania parasites, in a highly endemic area. Noteworthy, this report has unveiled the complexity of performing a RFT for anti-CVL vaccines in Brazil, which may be helpful for designing of future studies.
Authors: E G Lopes; A P Sevá; F Ferreira; C M Nunes; L B Keid; R M Hiramoto; H L Ferreira; T M F S Oliveira; F G Ovallos; E A B Galati; T J Villegas; D V Bortoletto; S Y O B Valadas; R M Soares Journal: Epidemiol Infect Date: 2018-01-18 Impact factor: 4.434
Authors: Raul Rio Ribeiro; Marilene Suzan Marques Michalick; Manoel Eduardo da Silva; Cristiano Cheim Peixoto Dos Santos; Frédéric Jean Georges Frézard; Sydnei Magno da Silva Journal: Biomed Res Int Date: 2018-03-29 Impact factor: 3.411
Authors: Ana Paula M M Almeida; Leopoldo F M Machado; Daniel Doro; Frederico C Nascimento; Leonardo Damasceno; Ricardo Tostes Gazzinelli; Ana Paula Fernandes; Caroline Junqueira Journal: Front Immunol Date: 2018-03-15 Impact factor: 7.561
Authors: Sara Sorgi; Vivian Bonezi; Mariana R Dominguez; Alba Marina Gimenez; Irina Dobrescu; Silvia Boscardin; Helder I Nakaya; Daniel Y Bargieri; Irene S Soares; Eduardo L V Silveira Journal: J Venom Anim Toxins Incl Trop Dis Date: 2020-04-06
Authors: Anna Raquel Ribeiro Dos Santos; Ângela Vieira Serufo; Maria Marta Figueiredo; Lara Carvalho Godoi; Jéssica Gardone Vitório; Andreza Pain Marcelino; Daniel Moreira de Avelar; Fernandes Tenório Gomes Rodrigues; George Luiz Lins Machado-Coelho; Fernanda Alvarenga Cardoso Medeiros; Selma Maria Bezerra Jerônimo; Edward José de Oliveira; Frederico Crepaldi Nascimento; Santuza Maria Ribeiro Teixeira; Ricardo Tostes Gazzinelli; Ronaldo Alves Pinto Nagem; Ana Paula Fernandes Journal: Mem Inst Oswaldo Cruz Date: 2019-02-04 Impact factor: 2.743